n & g pharma limited
n & g pharma limited Company Information
Company Number
09099448
Next Accounts
Mar 2025
Industry
Wholesale of pharmaceutical goods
Shareholders
charnjit bhandal
mrs ravinder bhandal
Group Structure
View All
Contact
Registered Address
suite 2 the old bank, 2 coventry street, stourbridge, west midlands, DY8 1EP
Website
accord-healthcare.comn & g pharma limited Estimated Valuation
Pomanda estimates the enterprise value of N & G PHARMA LIMITED at £2.2m based on a Turnover of £5.1m and 0.44x industry multiple (adjusted for size and gross margin).
n & g pharma limited Estimated Valuation
Pomanda estimates the enterprise value of N & G PHARMA LIMITED at £903.2k based on an EBITDA of £211.7k and a 4.27x industry multiple (adjusted for size and gross margin).
n & g pharma limited Estimated Valuation
Pomanda estimates the enterprise value of N & G PHARMA LIMITED at £840.7k based on Net Assets of £426.5k and 1.97x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
N & G Pharma Limited Overview
N & G Pharma Limited is a live company located in stourbridge, DY8 1EP with a Companies House number of 09099448. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in June 2014, it's largest shareholder is charnjit bhandal with a 50% stake. N & G Pharma Limited is a established, mid sized company, Pomanda has estimated its turnover at £5.1m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
N & G Pharma Limited Health Check
Pomanda's financial health check has awarded N & G Pharma Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 6 areas for improvement. Company Health Check FAQs
2 Strong
3 Regular
6 Weak
Size
annual sales of £5.1m, make it smaller than the average company (£24.6m)
- N & G Pharma Limited
£24.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 102%, show it is growing at a faster rate (5.1%)
- N & G Pharma Limited
5.1% - Industry AVG
Production
with a gross margin of 24.8%, this company has a comparable cost of product (24.8%)
- N & G Pharma Limited
24.8% - Industry AVG
Profitability
an operating margin of 4% make it as profitable than the average company (3.9%)
- N & G Pharma Limited
3.9% - Industry AVG
Employees
with 3 employees, this is below the industry average (37)
3 - N & G Pharma Limited
37 - Industry AVG
Pay Structure
on an average salary of £70.6k, the company has an equivalent pay structure (£70.6k)
- N & G Pharma Limited
£70.6k - Industry AVG
Efficiency
resulting in sales per employee of £1.7m, this is more efficient (£675.6k)
- N & G Pharma Limited
£675.6k - Industry AVG
Debtor Days
it gets paid by customers after 100 days, this is later than average (60 days)
- N & G Pharma Limited
60 days - Industry AVG
Creditor Days
its suppliers are paid after 23 days, this is quicker than average (32 days)
- N & G Pharma Limited
32 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- N & G Pharma Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (10 weeks)
0 weeks - N & G Pharma Limited
10 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 70.6%, this is a higher level of debt than the average (57.5%)
70.6% - N & G Pharma Limited
57.5% - Industry AVG
N & G PHARMA LIMITED financials
N & G Pharma Limited's latest turnover from June 2023 is estimated at £5.1 million and the company has net assets of £426.5 thousand. According to their latest financial statements, N & G Pharma Limited has 3 employees and maintains cash reserves of £9 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||
| Other Income Or Grants | |||||||||
| Cost Of Sales | |||||||||
| Gross Profit | |||||||||
| Admin Expenses | |||||||||
| Operating Profit | |||||||||
| Interest Payable | |||||||||
| Interest Receivable | |||||||||
| Pre-Tax Profit | |||||||||
| Tax | |||||||||
| Profit After Tax | |||||||||
| Dividends Paid | |||||||||
| Retained Profit | |||||||||
| Employee Costs | |||||||||
| Number Of Employees | 3 | 3 | 1 | ||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 35,264 | 42,233 | 6,526 | 7,486 | 5,583 | 6,568 | 7,727 | 9,091 | 10,695 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 35,264 | 42,233 | 6,526 | 7,486 | 5,583 | 6,568 | 7,727 | 9,091 | 10,695 |
| Stock & work in progress | 0 | 267,745 | 249,435 | 80,555 | 0 | 62,946 | 74,802 | 165,802 | 344,619 |
| Trade Debtors | 1,398,990 | 1,058,528 | 277,821 | 0 | 0 | 425,998 | 600,360 | 471,871 | 460,633 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 6,845 | 3,800 | 3,800 | 22,391 | 4,479 | 18,699 | 0 | 0 | 0 |
| Cash | 8,981 | 7,136 | 17,432 | 3,422 | 1,070 | 6,829 | 49,020 | 6,620 | 53,516 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 1,414,816 | 1,337,209 | 548,488 | 106,368 | 5,549 | 514,472 | 724,182 | 644,293 | 858,768 |
| total assets | 1,450,080 | 1,379,442 | 555,014 | 113,854 | 11,132 | 521,040 | 731,909 | 653,384 | 869,463 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 249,933 | 695,316 | 447,440 | 104,964 | 8,081 | 398,337 | 389,973 | 443,321 | 892,938 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 764,786 | 403,436 | 43,810 | 25,074 | 10,328 | 118,881 | 0 | 0 | 0 |
| total current liabilities | 1,014,719 | 1,098,752 | 491,250 | 130,038 | 18,409 | 517,218 | 389,973 | 443,321 | 892,938 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 8,816 | 8,024 | 1,422 | 1,422 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 8,816 | 8,024 | 1,422 | 1,422 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 1,023,535 | 1,106,776 | 492,672 | 131,460 | 18,409 | 517,218 | 389,973 | 443,321 | 892,938 |
| net assets | 426,545 | 272,666 | 62,342 | -17,606 | -7,277 | 3,822 | 341,936 | 210,063 | -23,475 |
| total shareholders funds | 426,545 | 272,666 | 62,342 | -17,606 | -7,277 | 3,822 | 341,936 | 210,063 | -23,475 |
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Profit | |||||||||
| Depreciation | 6,969 | 4,522 | 1,712 | 1,707 | 985 | 1,159 | 1,364 | 1,604 | 713 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | |||||||||
| Stock | -267,745 | 18,310 | 168,880 | 80,555 | -62,946 | -11,856 | -91,000 | -178,817 | 344,619 |
| Debtors | 343,507 | 780,707 | 259,230 | 17,912 | -440,218 | -155,663 | 128,489 | 11,238 | 460,633 |
| Creditors | -445,383 | 247,876 | 342,476 | 96,883 | -390,256 | 8,364 | -53,348 | -449,617 | 892,938 |
| Accruals and Deferred Income | 361,350 | 359,626 | 18,736 | 14,746 | -108,553 | 118,881 | 0 | 0 | 0 |
| Deferred Taxes & Provisions | 792 | 6,602 | 0 | 1,422 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||
| Investing Activities | |||||||||
| capital expenditure | |||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||
| Financing Activities | |||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||
| interest | |||||||||
| cash flow from financing | |||||||||
| cash and cash equivalents | |||||||||
| cash | 1,845 | -10,296 | 14,010 | 2,352 | -5,759 | -42,191 | 42,400 | -46,896 | 53,516 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 1,845 | -10,296 | 14,010 | 2,352 | -5,759 | -42,191 | 42,400 | -46,896 | 53,516 |
n & g pharma limited Credit Report and Business Information
N & G Pharma Limited Competitor Analysis
Perform a competitor analysis for n & g pharma limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mid companies, companies in DY8 area or any other competitors across 12 key performance metrics.
n & g pharma limited Ownership
N & G PHARMA LIMITED group structure
N & G Pharma Limited has no subsidiary companies.
Ultimate parent company
N & G PHARMA LIMITED
09099448
n & g pharma limited directors
N & G Pharma Limited currently has 2 directors. The longest serving directors include Mr Peter Sidaway (Jun 2014) and Mr Charnjit Bhandal (Jan 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Peter Sidaway | England | 59 years | Jun 2014 | - | Director |
| Mr Charnjit Bhandal | 58 years | Jan 2019 | - | Director |
P&L
June 2023turnover
5.1m
+15%
operating profit
204.8k
0%
gross margin
24.8%
+3%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2023net assets
426.5k
+0.56%
total assets
1.5m
+0.05%
cash
9k
+0.26%
net assets
Total assets minus all liabilities
Similar Companies
n & g pharma limited company details
company number
09099448
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
June 2014
age
10
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
June 2023
previous names
N/A
accountant
-
auditor
-
address
suite 2 the old bank, 2 coventry street, stourbridge, west midlands, DY8 1EP
Bank
-
Legal Advisor
-
n & g pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to n & g pharma limited. Currently there are 1 open charges and 0 have been satisfied in the past.
n & g pharma limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for N & G PHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.
n & g pharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
